PainChek Competitors

1st Group (ASX:1ST) and PainChek (ASX:PCK) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Earnings & Valuation

This table compares 1st Group and PainChek's revenue, earnings per share and valuation.

1st Group has higher revenue and earnings than PainChek.

Profitability

This table compares 1st Group and PainChek's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for 1st Group and PainChek, as provided by MarketBeat.com.

Summary

1st Group beats PainChek on 2 of the 3 factors compared between the two stocks.

PainChek (ASX:PCK) and Alcidion Group (ASX:ALC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Profitability

This table compares PainChek and Alcidion Group's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares PainChek and Alcidion Group's top-line revenue, earnings per share (EPS) and valuation.

Alcidion Group has higher revenue and earnings than PainChek.

Analyst Ratings

This is a breakdown of current recommendations and price targets for PainChek and Alcidion Group, as reported by MarketBeat.

Summary

Alcidion Group beats PainChek on 3 of the 3 factors compared between the two stocks.

Binovi Technologies (OTCMKTS:BNVIF) and PainChek (ASX:PCK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Earnings & Valuation

This table compares Binovi Technologies and PainChek's gross revenue, earnings per share (EPS) and valuation.

Binovi Technologies has higher earnings, but lower revenue than PainChek.

Analyst Recommendations

This is a summary of recent recommendations for Binovi Technologies and PainChek, as provided by MarketBeat.com.

Profitability

This table compares Binovi Technologies and PainChek's net margins, return on equity and return on assets.

Summary

PainChek beats Binovi Technologies on 1 of the 1 factors compared between the two stocks.

PainChek (ASX:PCK) and Cann American (CNSX:CNNA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares PainChek and Cann American's revenue, earnings per share (EPS) and valuation.

Cann American has lower revenue, but higher earnings than PainChek.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for PainChek and Cann American, as provided by MarketBeat.

Profitability

This table compares PainChek and Cann American's net margins, return on equity and return on assets.

Summary

PainChek beats Cann American on 1 of the 1 factors compared between the two stocks.

PainChek (ASX:PCK) and CannaOne Technologies (OTCMKTS:CNONF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares PainChek and CannaOne Technologies' revenue, earnings per share (EPS) and valuation.

CannaOne Technologies has lower revenue, but higher earnings than PainChek.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for PainChek and CannaOne Technologies, as provided by MarketBeat.

Profitability

This table compares PainChek and CannaOne Technologies' net margins, return on equity and return on assets.

Summary

PainChek beats CannaOne Technologies on 1 of the 1 factors compared between the two stocks.

PainChek (ASX:PCK) and CloudMD Software & Services (OTCMKTS:DOCRF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares PainChek and CloudMD Software & Services' revenue, earnings per share (EPS) and valuation.

CloudMD Software & Services has lower revenue, but higher earnings than PainChek.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for PainChek and CloudMD Software & Services, as provided by MarketBeat.

CloudMD Software & Services has a consensus target price of $3.3750, indicating a potential upside of 97.37%.

Profitability

This table compares PainChek and CloudMD Software & Services' net margins, return on equity and return on assets.